Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694932 | 0.89 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30738431 | 0.89 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11446154 | 0.88 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1238330 | 0.87 | HDAC3 (0.66) | MAPK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5968938 | 0.86 | HDAC3 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL26624031 | 0.86 | HDAC3 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28824437 | 0.86 | HDAC3 (0.69) | MAPK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27291375 | 0.85 | HDAC3 (0.84) | MAPK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30738307 | 0.85 | HPGD (0.68) | MAPK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1818573 | 0.85 | HPGD (0.68) | MAPK1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1184194-C | Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide | BAYER AG (DE) | 2005-01-12 | — | — | CN | claimed |
| EP-1268400-B1 | METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE | BAYER CHEMICALS AG (DE) | 2004-08-11 | — | — | EP | claimed |
| US-20040030183-A1 | Method for producing N-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound N-(4-bromo-2-methylphenyl)butanamide | RODEFELD LARS (DE) | 2004-02-12 | — | — | US | claimed |
| US-6620962-B2 | Reacting toluidine and butyryl chloride; then bromination; using palladium catalyst | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | claimed |
| CN-1419535-A | Process for producing N-butyryl-4-amino-3-methyl-benzoic acid methyl ester and novel compound N- (4-bromo-2-methylphenyl) butyramide | BAYER AG (DE) | 2003-05-21 | — | — | CN | claimed |
| US-20030065211-A1 | Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide | LANXESS DEUTSCHLAND GMBH (DE) | 2003-04-03 | — | — | US | claimed |
| EP-1268400-A2 | METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE | Bayer Aktiengesellschaft (DE) | 2003-01-02 | — | — | EP | claimed |
| WO-2001072690-A2 | METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | claimed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| CN-119968368-A | Amide compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-05-09 | — | — | CN | disclosed |
| CN-117402156-A | Amide compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024008196-A1 | CLASS OF AMIDE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2024-01-11 | — | — | WO | disclosed |
| CN-109369649-A | Matrine amide derivatives and its preparation method and application | 常州大学 | 2019-02-22 | — | — | CN | disclosed |
| EP-2956452-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-03-21 | — | — | EP | disclosed |
| US-20030065211-A1 | Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide | LANXESS DEUTSCHLAND GMBH (DE) | 2003-04-03 | — | — | US | disclosed |
| EP-1268400-A2 | METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE | Bayer Aktiengesellschaft (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1216243-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | Advanced Medicine, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001072690-A2 | METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001025234-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | ADVANCED MEDICINE, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065211-A1 | Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide | GABBR2, BBOX1, GABRB3 | MAPK1 4342/4885HDAC3 833/4885HDAC4 737/4885 |
| US-20040030183-A1 | Method for producing N-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound N-(4-bromo-2-methylphenyl)butanamide | BRD4, GABRB3, GABBR2 | MAPK1 3623/4885HDAC3 310/4885HDAC4 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.